SCHEMBL4052966

SCHEMBL4052966

ClC(Cl)(Cl)c1ncon1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1101984 0.74
SCHEMBL14152763 0.70
SCHEMBL30471938 0.70
SCHEMBL2047045 0.70
Hydrochloric Acid SCHEMBL14151949 0.69 CNR2 (0.30)
SCHEMBL16077055 0.65 CNR2 (0.36)
SCHEMBL17100811 0.62 CYP19A1 (0.34)
SCHEMBL1436986 0.59 HDAC8 (0.35)
SCHEMBL690070 0.57
SCHEMBL15382251 0.57

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022092687-A1 COMPOSITION COMPRISING PROTEIN EXPRESSION INHIBITOR FOR ANTIOXIDATION, ANTIINFLAMMATION, AND DEMENTIA PREVENTION OR ALLEVIATION, AND USE THEREOF 서울대학교산학협력단 2022-05-05 WO disclosed
EP-1797094-A4 1,3-DISUBSTITUTED HETEROARYL NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2009-06-03 EP disclosed
US-20070293515-A1 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists MERCK SHARP & DOHME CORP. 2007-12-20 US disclosed
EP-1797094-A2 1,3-DISUBSTITUTED HETEROARYL NMDA/NR2B ANTAGONISTS Merck &amp; Co. Inc. (US) 2007-06-20 EP disclosed
WO-2006017409-A2 1,3-DISUBSTITUTED HETEROARYL NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2006-02-16 WO disclosed
EP-0273534-A2 Oxa(thia)diazole derivatives NIPPON SODA CO., LTD. (JP) 1988-07-06 EP disclosed